.svg){kind=logo}
.svg){kind=logo}
MENU
CLOSE
.svg){kind=icon}
MENU
CLOSE
Moxidectin Development Update: A promising additional tool to accelerate elimination of onchocerciasis
Presentation by Sally Kinrade, Project Leader, Onchocerciasis and Lymphatic Filariasis
Our 2022-23 Annual Report documents our medicine development progress, highlights our achievements over the year, and presents our approach to looking forward and continuing our global presence.
Medicines Development for Global Health (MDGH) develops new medicines for people and communities who are disadvantaged by the traditional consideration of market returns.
In 2018, we became the first solo not-for-profit company to achieve FDA approval for a novel medicine, when we registered moxidectin, the first new treatment for river blindness (onchocerciasis) in 20 years. Supported by our collaborators, we are working towards making a lasting change in the lives of people affected by neglected diseases.
Of the approximately 400 New Drug Applications (NDAs) approved in the years 2009 to 2020, only 10 were for neglected infectious diseases, which affect more than a billion people globally. As a social enterprise, we take an innovative approach to developing new and improved treatments for neglected diseases, helping to elevate the health status of affected communities in low- and middle-income countries.
We are addressing important and unmet medical needs in global health through the development and delivery of new medicines. Our development model is resource-efficient and cost-effective, and built on identifying and integrating the necessary expertise from each part of the development pathway at the time that expertise is needed.
We work constructively to address global health inequities, but our work is just one piece of a larger puzzle. Our team relies on strong collaboration networks and continuously seeks fruitful and effective partnerships to increase our chances of reducing the burden of neglected diseases.
Medicines Development for Global Health Limited is a not-for-profit pharmaceutical company incorporated in Australia (Australian Company Number 116 977 523) and registered as a charity with the Australian Charities and Not-for-profits Commission. Any donation made through this website will go towards the work of MDGH Australia. Donations made to the United Kingdom or United States affiliate offices fund the work of that entity.
Follow our work by signing up for our newsletter
MDGH respectfully acknowledges the Traditional Owners of the land on which our office is located, the Wurundjeri people of the Kulin Nation, and pay our respect to their Elders past, present and emerging.
Medicines Development for Global Health Limited.
Level 1, 18 Kavanagh Street Southbank Victoria 3006 Australia.
ABN: 79 116 977 523
